The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Sarcomatoid dedifferentiation is an uncommon feature that can occur in most histological
subtypes of renal cell carcinomas (RCCs) and carries a decidedly poor prognosis …

Background Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC)
have a poor prognosis and limited therapeutic options. First-line nivolumab plus ipilimumab …

Background Among patients with advanced renal cell carcinoma (RCC), those with
sarcomatoid histology (sRCC) have the poorest prognosis. This analysis assessed the …

Immunotherapy has revolutionized the treatment landscape for many cancer types. The
treatment for renal cell carcinoma (RCC) has especially evolved in recent years, from …

Simple Summary Immunotherapy-based treatment options have become standard of care in
metastatic renal cell carcinoma. Despite significant improvement in overall survival with …

Non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous group of malignancies
that represents 25% of renal cell carcinoma (RCC) cases. Treatment for non-clear cell …

Abstract Purpose of Review Historically, kidney cancer was diagnosed as either clear cell
renal carcinoma (ccRCC) or non-clear cell renal carcinoma (nccRCC). With further research …

Approximately 400,000 patients are diagnosed with kidney cancer annually worldwide,
leading to approximately 170,000 deaths. Renal cell carcinoma (RCC) accounts for more …

Objectives To assess the impact of histological variants on survival and response to
treatment with pembrolizumab in patients with chemo‐resistant urothelial carcinoma (UC) …